Ucb Biopharma Sprl

Ucbbiopharma Srl

Sanofi

Martin Alexander Lowe

Zhaoning Zhu

John Robert Porter

Boris Kroeplien

Victoria Elizabeth Jackson

Malcolm Maccoss

James Andrew Johnson

Richard David Taylor

Fabien Claude Lecomte

Teresa De Haro Garcia

Daniel Christopher Brookings

Timothy John Norman

Martin Clive Hutchings

Matthew Duncan Selby

James Thomas Reuberson

Joanna Rachel Quincey

Helen Tracey Horsley

Anne Marie Foley

Michael Alan Shaw

Ellen Olivia Gallimore

Julien Alistair Brown

Craig Johnstone

Jag Paul Heer

Pui Leng Loke

Jonathan Bentley

Luce Lépissier

Mark Daniel Calmiano

Gareth Neil Brace

Jean Keyaerts

Laura Gleave

Christopher Francis Palmer

Gregory Foulkes

James Madden

Michael Louis Robert Deligny

Muhammed Kamal Uddin

Alexander Heifetz

Prafulkumar Tulshibhai Chovatia

Giancarlo Trani

Thomas Paul Cain

Deborah Leigh

Severine Danielle Jones

Donald Smyth

Lloyd Malcolm King

Rebecca Louise Charlton

Trevor Morgan

Sarah Emily Richardson

Anthony John Richardson

Laura Claire Reed

Praful Tulshi Chovatia

Ajay Mandal

Yolanda Pérez-Fuertes

Laura Jane Gleave

Jonathan Mark Bentley

Michaël Louis Robert Deligny

Luce Elsa LÉPISSIER

The application relates to a series of 2-imino-6-methylhexahydropyrimidin-4-one derivatives and 3-imino-5-methyl-1,2,4-thiadiazinane 1,1-dioxide derivatives of formula (I), substituted by an arylaminophenyl or heteroarylaminophenyl moiety. The compounds are potent inhibitors of the growth and propagation of theparasite in human blood and thus useful as pharmaceutical agents for the treatment of malaria. 

Antimalarial hexahydropyrimidine analogues

A series of 2-imino-6-methyltetrahydropyrimidin-4(1H)-one derivatives, substituted in the 6-position by a phenyl moiety which in turn is meta-substituted by an optionally substituted unsaturated fused bicyclic ring system containing at least one nitrogen atom, being selective inhibitors of plasmepsin V activity, are beneficial as pharmaceutical agents, especially in the treatment of malaria.

Iminotetrahydropyrimidinone derivatives as plasmepsin V inhibitors

A series of substituted fused pentacyclic benzimidazole derivatives, and analogues thereof, being potent modulators of human TNF&#x3b1; activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

Fused pentacyclic imidazole derivatives as modulators of TNF activity

A series of 3-imino-5-methyl-1,2,4-thiadiazinane 1,1-dioxide derivatives of formula (I), substituted in the 5-position by a phenyl moiety NH which in turn is meta-substituted by an optionally substituted fused bicyclic heteroaromatic ring system containing at least one nitrogen atom, being selective inhibitors of plasmepsin V activity, are beneficial as pharmaceutical agents, especially in the treatment of malaria. 

Iminothiadiazinane dioxide derivatives as plasmepsin V inhibitors

A series of substituted 3,4-dihydro-2H-.1,4-benzoxazin-3-one derivatives, and analogs thereof, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neuradegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. 

Substituted benzo[b][1,4]oxazines and pyrido[3,2-b][1,4]oxazines as modulators of tumor necrosis factor activity

A series of substituted purine derivatives, being potent modulators of human TNF&#x3b1; activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

Purine derivatives as modulators of TNF activity

A series of substituted 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine derivatives, being potent treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

Tetrahydroimidazopyridine derivatives as modulators of TNF activity

A series of substituted 4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. 

A series of benzimidazole derivatives, being potent modulators of human TNF&#x3b1; activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

TNF -&#x3b1; modulating benzimidazoles

A series of imidazo[1,2-a]pyridine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. 

Imidazopyridine derivatives as modulators of TNF activity

Growing community of inventors

Slough, United Kingdom

Martin Alexander Lowe